lower narrow-moat iqvia fair valu estim
due challeng
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
iqvia formerli quintilesim result merger
quintil lead late-stag contract research organ
im health domin player life scienc data analyt
combin compani becom entrench leader
cro space life scienc data analyt
result merger compani lead real-world evid
data sourc patient record medic claim
use creat clinic evid regulatori approv
revenu come research
develop segment outsourc clinic research
technolog analyt segment legaci im health
cloud solut life scienc real-world data trial offer
contract sale research develop
segment focus late-stag research requir thousand
patient across globe iqvia easili belong top tier
larg global infrastructur win contract
size mean work clinic trial
competitor sharpen clinic regulatori expertis
network client
compani comprehens data set de-identifi patient
record script data enhanc abil attract retain
healthcar custom throughout life cycl drug product
iqvia compil data sourc includ
pharmaci medic claim electron health record
access million patient record unmatch
databas layer proprietari methodolog enabl client
set inform strategi effect commerci
drug result busi command price premium
high retent rate exist client access data help
inform patient identif clinic trial success trial
design compani also leverag cohort
de-identifi patient data set real-world evid trial
data use lieu tradit clinic trial cohort
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
iqvia result merger quintil lead global contract
research organ im health lead healthcar data
analyt provid cro segment focus primarili provid
outsourc late-stag clinic trial pharmaceut devic
technolog servic client healthcar industri includ
pharmaceut compani provid payer policymak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
iqvia post underli cro demand remain
iqvia report first-quart result line
expect manag provid new guidanc
full year previous model
estim top line plan lower revenu
expect
get within
manag guid midpoint billion
low-single-digit declin lower fair valu
estim low-single-digit percent compani
assum site access
second quarter third fourth
slightli longer period disrupt
previous model late march assum roughli
site access week
overal think compani well posit
withstand crisi despit oper challeng
think underli demand iqvia servic remain
strong provid mission-crit servic
biopharma industri believ demonstr
strength
intang switch cost
underpin compani narrow econom moat
clinic trial revenu first quarter billion
constant currenc last year
point impact lower reimburs expens
expect compani combat challeng pose
research develop segment
remot site monitor at-hom servic telehealth
visit patient recruit site monitor remain
sever impact travel restrict shutdown
underli demand busi remain strong
new busi win bring backlog billion
last year
technolog segment contribut billion revenu
constant currenc last year
segment benefit substanti recur revenu base
expect modest impact due challeng
virtual sell effort pleas hear
slowdown implement
good news given compani lot new busi
last year
contract sale segment contribut million
constant currenc segment
shelter much impact first quarter expect
difficulti virtual sell sever impact
segment next coupl quarter model single-
digit declin year small busi segment
lower fair valu estim per share
adjust model manag
issu new guidanc relat impact
clinic trial start enrol guidanc includ
site inaccess extend slightli longer
previous model model single-digit
declin total revenu compar
also assum lower demand smaller biotech affect
otherwis expect solid recoveri measur
stop spread pandem loosen around world
long term believ iqvia gain share
cro space research develop segment
grow slightli higher clip industri impli
billion revenu believ
technolog analyt segment grow faster rate
life scienc data analyt play larger role
clinic trial mission-crit process
biopharma industri model billion revenu
long term see opportun cut cost
research develop segment model adjust
ebitda margin improv roughli basi point
expect iqvia push fixed-pric contract
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
competit data analyt space
wide rang outcom relat clinic trial start
enrol coronaviru pandem
bear-cas scenario assum amplifi impact
shutdown site closur clinic trial start
contract margin case revenu
billion oper margin
year forecast result bear-cas
fair valu estim per share
bull case assum site closur lockdown
remain place shorter period time quicker
enrol faster trial start monitor return
normal case assum pullback biotech
fund case firm earn billion
revenu case assum iqvia improv
gross oper margin util capac
effici abl adapt better trial
cancel result mid-cycle oper margin
bull-cas fair valu estim per
iqvia leader clinic research healthcar data
nearli everi major biotechnolog pharmaceut
compani pay
proprietari data clinic develop expertis
posit firm well closest peer
intang asset high switch cost underpin
servic think
iqvia result merger im health
lead data analyt compani life scienc
quintil global cro largest market share
strateg advantag merger initi clear
im health provid data biotechnolog
pharmaceut compani rather lack
contract visibl cost allow
retain higher margin think room
margin expans technolog analyt segment
throughout explicit forecast model basi
point ebitda margin improv addit
autom help reduc cost expect mix play
role growth higher-margin real-world evid
trial use de-identifi patient data cohort evid
regulatori approv iqvia move
implement phase offer relat
solut high-margin recur revenu drive margin
improv well
model long-term effect tax rate
believ firm continu grow acquir smaller
technolog analyt compani model
continu tuck-in acquisit assum
mid-cycle capit expenditur sale
believ iqvia medium uncertainti rate due
vulner biopharma research develop
spend outsourc level well potenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
cro demand im health capabl littl
overlap two firm threw question whether
firm would abl achiev synergi whether
integr would smooth view data
analyt capabl im health posit advantag
iqvia util vast patient data inform clinic trial
plan execut recent interest real-world
evid trial data sourc patient
record medic claim use creat clinic
increas import data analyt cro
space believ iqvia signific cro market
share unparallel data capabl best posit
lead way real-world evid work compar
peer compani sever real-world trial
on-going pharma client offer help
least one client get fda approv label expans
largest cro iqvia abil influenc
industri trend includ move data analyt
follow im health quintil merger sever
began build data capabl
acquisit partnership albeit lesser degre
firm cro busi moatworthi right
infrastructur diversifi client base
late-stag exposur believ exposur late-stag
clinic trial crucial moat cro space
late-stag trial larger scope complex often
multi-national higher risk failur
differenti global leverag expertis
shorten clinic trial time frame ensur accuraci
precis iqvia maintain top spot cro market
share cro revenu come late-stag
work firm diversifi client base split
small/mids custom
larger biotech
pharmaceut compani broad portfolio
central
commerci believ diversifi client base
strengthen iqvia competit advantag small/mids
client like need full outsourc solut
partnership high switch cost choos one
trust funnel new
iqvia data analyt busi also deserv moat
due intang asset switch cost
proprietari data set sourc sourc
pharmaci claim registri patient record
scale data best-in-class analyt
technolog iqvia layer data creat high barrier
entri closest competitor iqvia technolog side
symphoni health offer smaller portfolio
data servic much smaller market share
veeva compet iqvia client relationship
manag increasingli data analyt
veeva captur signific share life scienc
cloud servic space believ iqvia reput
asset data space unparallel evidenc
retent rate top client
biotech pharmaceut client use iqvia servic
mission-crit function plan new product
launch forecast revenu market sell
client like continu choos trust iqvia data
relat solut preserv continu illustr
high switch cost labcorp also strong contend
relat data cro busi pair
lab diagnost arm gener
impress set patient data howev believ
iqvia lengthi experi breadth data serv
high bar competitor
believ iqvia stabl moat trend competit
dynam cro data space fundament
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
shift compani strategi consult
technolog aspect busi grow import
iqvia remain well posit space due
expans intang asset opinion believ
firm continu hold top share cro space due
exposur late-stag trial breadth
expertis complex diseas area diversifi client
base recent book backlog metric indic
cro industri continu grow
percentag outsourc grow slowli
data space iqvia advantag util
vast proprietari data capabl inform real-world
evid strategi sourc patient record
medic claim provid data regulatori approv
fda biopharma industri voic need
modern clinic trial process heavili
reli technolog believ difficulti obtain
extens databas develop best-in-class
technolog creat high barrier entri believ
grow market support smaller competitor
symphoni veeva without endang iqvia narrow
moat would consid upgrad posit moat trend
rate signific polici come fda
would make real-world evid preval
entrench iqvia data technolog advantag
would consid downgrad neg moat trend rate
shift data privaci regul interoper
initi lower barrier entri make easier
competitor encroach compani lead patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oiqvia lead posit outsourc clinic trial
allow creat sticki client relationship
hone clinic regulatori expertis
traction among client fail gain traction
oth merger im health provid access
unparallel databas patient data
strengthen clinic trial offer
oth on-going shift outsourc provid
cro industri steadi growth regardless
trend global research develop spend
oiqvia contract sale segment larg no-moat
busi lack competit advantag
ochang data privaci regul could
make easier competitor gain access de-
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
iqvia decent financi health strong cash flow
gener clinic research technolog
busi off-set above-averag debt load
compani continu stay highli leverag even year
merger substanti portion capit fund
share buyback end compani
billion total gross debt total debt
time adjust ebitda year-end firm held
million cash balanc sheet expect healthi cash
gener clinic research technolog
segment concern compani
meet debt oblig matur
iqvia long-term debt
floating-r debt expect compani alloc
capit share buyback smaller acquisit
throughout explicit forecast period
believ iqvia medium uncertainti rate
risk off-set larg diversifi revenu base cro
industri highli depend spend
outsourc prefer custom base biotech
pharmaceut compani believ
decreas spend outsourc like
near term left expos risk
biopharma fund constrain chang
drug approv regulatori landscap biopharma
industri face macroeconom headwind
wide rang outcom relat clinic trial
start enrol coronaviru pandem iqvia
largest player cro space
well-diversifi revenu base singl client make
sale result think
compani well diversifi client concentr risk
individu trial cancel sizabl
impact cro busi result compani also
suscept shift clinic trial data privaci
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
highli depend
regul leader real-world evid iqvia
cooper real-world evid offer
worth premium complet embrac fda
regulatori entiti compani oper
depend heavili use de-identifi patient data
technolog analyt segment well
research develop segment chang privaci
guidelin could affect suppli use data make
easier competitor amass patient data
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
chairman board/president/
repres date owner name posit common share held report holder issuer
leadership team appropri experi span
consult clinic research healthcar data
analyt quintil im health merger
strateg bet futur data analyt
clinic research space note transact
significantli decreas level adjust return
invest capit roic believ one
import measur sharehold valu prior
merger quintil busi enjoy sky-high return
invest capit care execut manag
believ roic increas steadili compani
integr continu watch iqvia
leverag im data analyt asset
merger late bousbib former im
health ceo board chairman took posit
combin compani bousbib led im health sinc
hold sever leadership role unit
technolog think compani capit alloc
rel shareholder-friendli leadership
merger former quintil ceo thoma pike serv
vice chairman presid solut
retir compani coupl month later
pike earli departur rais eyebrow think cro
busi remain steadi hand leadership
 richard staub join quintil
acquisit specialti cro novella clinic
technolog segment led kevin knightli work
im year jon resnick presid
real-world analyt solut work im
share
fund
share
fund
capit research manag compani
capit alloc decis sinc merger larg
funnel toward develop busi smaller
tech-focus acquisit heighten
expenditur invest total billion
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
think invest help secur
acceler revenu growth firm long term
continu integr data analyt cro
busi could help strengthen compani intang
asset switch cost howev manag
continu util debt fund heavi share buyback
total billion repurchas sinc merger
question whether polici coupl fact
execut compens tie long-term incent
larg base adjust ep growth best
prefer see chairman ceo role
separ remaind board made
independ director director
design group previous substanti
sharehold includ tpg canada pension
invest board bain capit ownership stake
substanti decreas year iqvia bought
back share tpg cppib leonard green took im
privat presenc privat equiti
uncommon cro industri mani top global player
previous restructur current firm
period privat equiti ownership
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
iqvia post underli cro demand remain
iqvia report first-quart result line
expect manag provid new guidanc
full year previous model
estim top line plan lower revenu
expect
get within
manag guid midpoint billion
low-single-digit declin lower fair valu
estim low-single-digit percent compani
assum site access
second quarter third fourth
slightli longer period disrupt
previous model late march assum roughli
site access week
overal think compani well posit
withstand crisi despit oper challeng
think underli demand iqvia servic remain
strong provid mission-crit servic
biopharma industri believ demonstr
strength
intang switch cost
underpin compani narrow econom moat
clinic trial revenu first quarter billion
constant currenc last year
point impact lower reimburs expens
expect compani combat challeng pose
research develop segment
remot site monitor at-hom servic telehealth
visit patient recruit site monitor remain
sever impact travel restrict shutdown
underli demand busi remain strong
new busi win bring backlog billion
last year
technolog segment contribut billion revenu
constant currenc last year
segment benefit substanti recur revenu base
expect modest impact due challeng
virtual sell effort pleas hear
slowdown implement
good news given compani lot new busi
last year
contract sale segment contribut million
constant currenc segment
shelter much impact first quarter expect
difficulti virtual sell sever impact
segment next coupl quarter model single-
digit declin year small busi segment
affect clinic trial start patient
recruit lower fve late-stag
pandem grip healthcar system
across globe expect continu delay clinic trial
challeng patient enrol second
quarter expect weigh backlog convers
iqvia icon health syneo health
adjust model account short-term impact
revenu difficulti trial monitor patient
recruit expect lower demand small
biotech client pullback fund like
riskier compani cost side model flat slightli
declin margin next two year result
fair valu
estim iqvia icon respect
low-double-digit percentag decreas health
syneo respect maintain
narrow moat rate contract research
organ base intang switch cost
think cover well equip
mitig impact much possibl implement
remot monitor pull forward virtual
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
work view sector overvalu earli
iqvia syneo health trade modest discount
fair valu market discount name
due higher leverag anticip
liquid concern even bear case iqvia end
year net leverag ratio time adjust ebitda
syneo priorit debt paydown
last two year end year ratio time
iqvia maintain billion debt princip
mostli due later balanc sheet
reinvest busi heavili repurchas
share addit market-lead cro busi
iqvia also earn roughli revenu technolog
analyt busi expect see minim
impact
trial impact vari case-by-cas basi expect
mani already-enrol trial especi treat
sever diseas continu site virtual trial
monitor at-hom servic somewhat mitig
impact site closur lockdown measur howev
despit expect trial start delay
new patient recruit halt delay
next sever week compar previou estim
model revenu growth lower roughli
basi point assum roughli one third
cro revenu tie site monitor
revenu delay next week
also think like see diminish
fund emerg cash-burn biotech
impact pandem hit global
economi lower busi win
think somewhat off-set pent-up demand
trial delay client
expect larger client remain fundament stabl
pharma research develop
spend continu grow midsingl digit
overal model revenu growth
coverag remain low singl digit strong
recoveri
narrow-moat syneo rumor explor sale
fair valu estim intact
march reuter report contract research
organ syneo health work invest
bank centerview partner explor sale
surpris news given two year
sinc merger inc research inventiv health
form narrow-moat syneo see
public like bidder report cite sourc
familiar matter emphas deal
certain maintain fair valu estim
per share given common presenc privat
equiti industri may see develop
news
syneo solid announc sever pharma
busi win throughout year firm healthi
year-over-year backlog growth year-end
clinic solut revenu grew prior year
reason see attract target
think public seem like like
acquir syneo paid debt steadili
sinc merger think total year-end debt
billion still hefti load acquir
iqvia largest public competitor stranger larg
deal focus acquisit technolog
side busi would surpris see deal
size cro side transact like
could spark anti-trust concern competitor recent
went public februari saddl
much debt larg purchas opinion icon
deal size would surpris departur
histor capit alloc decis
limit smaller deal lean balanc sheet
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
name oce continu well incumb veeva
remain entrench space iqvia abl
leverag trust name pharma client win
sever larg deal compani recent deploy
platform asia roch global roll-out anticip
deploy novo nordisk recent
deal astrazeneca scale think cloud
busi strong contributor
margin
revenu guidanc manag incorpor
million impact coronaviru outbreak due
delay closur trial site china well
million impact currenc headwind
middl year term new book growth
trade similar market cap syneo make
deal unlik view believ privat buy-out
like histor privat equiti playbook
involv leverag consolid syneo
alreadi hold substanti debt still launch post-
merger organiz chang note
taken privat held long-term debt
taken privat billion parexel
held million debt
iqvia report solid growth segment
fve chang feb
revenu billion slightli factset
analyst consensu expect adjust ebitda
million line expect manag
guidanc also fell within expect
anticip materi chang fair valu estim
per share measur iqvia busi
continu well technolog research
segment pois see high-single-digit growth year
expect adjust ebitda margin expand slowli driven
top-lin growth off-set intern invest
compani disclos data-driven clinic trial
offer drove impress million busi win
fourth quarter exclud reimburs pass-through
revenu think iqvia unmatch databas patient
inform analyt capabl continu drive
new clinic trial busi support intang
switch cost associ compani narrow
econom moat iqvia continu forefront
emerg technolog clinic research includ real-
world evid virtual trial compani seen
solid demand pharma virtual trial platform
virtual trial on-going larg pharma
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
